EverHint Lens - Apogee Therapeutics, Inc. (APGE) - Yahoo Finance Top Gainer (+20%) Stock Analysis - March 23, 2026
Analysis Date: 2026-03-23
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Executive Summary
Apogee Therapeutics, Inc. is currently trading at $79.25 (🟢 +20.00% today) with a market capitalization of $4.39B.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.
Price & Valuation
Current Price: $79.25 (at 2:18 PM ET)
Current Volume: 2.7M
Day Range: $76.17 - $81.46
52-Week Range: $26.20 - $84.56
P/E Ratio: -18.79
DCF Valuation: Overvalued
- Intrinsic Value (Unlevered DCF): $2.00
- Current Price: $79.25
- Discount/Premium: -97.5%
Levered DCF: $2.02 (-97.4%)
DCF analysis suggests the stock may be trading at a 97.5% premium to its intrinsic value.
DCF values calculated as of 2026-03-23. Underlying assumptions are not disclosed by the data provider. Levered vs unlevered can diverge materially for highly levered companies.
Market Context
Healthcare Sector: -1.11271% | Sector P/E: 26.16
Major Indices:
- S&P 500: $6599.88 (🟢 +1.44%)
- NASDAQ Composite: $21976.84 (🟢 +1.52%)
- Dow Jones Industrial Average: $46350.84 (🟢 +1.70%)
Peer Comparison
Peer comparison (11 companies):
- APGE - Apogee Therapeutics, Inc. ($79.25, +20.0%, $4.39B) ← Current
- CGON - CG Oncology, Inc. Common stock ($65.04, -0.1%, $5.49B)
- CELC - Celcuity Inc. ($107.12, +1.0%, $4.96B)
- XENE - Xenon Pharmaceuticals Inc. ($55.13, +0.3%, $4.59B)
- CNTA - Centessa Pharmaceuticals plc ($26.02, -3.8%, $3.50B)
- IRON - Disc Medicine, Inc. ($59.28, +1.9%, $2.26B)
- AAPG - ASCENTAGE PHARMA GROUP INTERNATIONAL ($21.91, +14.6%, $2.04B)
- ZLAB - Zai Lab Limited ($17.70, -2.1%, $1.96B)
- RARE - Ultragenyx Pharmaceutical Inc. ($19.89, +0.1%, $1.92B)
- SLNO - Soleno Therapeutics, Inc. ($32.37, -2.6%, $1.74B)
- LEGN - Legend Biotech Corporation ($17.36, -0.3%, $1.61B)
Financial Performance
Latest Quarter (2025-12-31):
- Revenue: $0.00M
- Net Income: $-69.39M
- EPS: $-1.03
Earnings Calendar
Next Earnings Report: 2026-05-11 (Before Market Open)
- EPS Estimate: $-1.12
Most Recent Report: 2026-03-02
- EPS: $-1.03 (Est: $-1.03) ✓ Beat
Historical Data: 17 earnings events tracked
Analyst Outlook
Analyst Price Target Consensus:
- Target: $105.63 (+33.3% upside)
- Range: $83.00 - $137.00
- Median: $99.00
Next Quarter Estimates (2027-12-31):
- EPS: $-1.34
Analyst Consensus
Overall Rating: Buy
Rating Distribution (20 total ratings):
- 🟢 Buy/Outperform: 18 (90.0%)
- ⚪ Hold/Neutral: 0 (0.0%)
- 🔴 Sell/Underperform: 0 (0.0%)
Recent Analyst Actions:
- RBC Capital (2026-01-22): Downgrade Outperform → Sector Perform
- Wolfe Research (2026-01-07): Initiate Peer Perform
- Stephens (2025-12-16): Initiate Overweight
- Deutsche Bank (2025-12-09): Initiate Buy
- Craig-Hallum (2025-11-03): Initiate Buy
Consensus based on 20 analyst ratings from major financial institutions
Trading Signals
Our technical analysis identified 2 trading signal(s) in the last 60 days:
- 2026-03-18: Ema10 Ema30 - EMA10_x_EMA30_Sell @ $66.77
- 2026-02-04: Sma20 Sma50 - SMA20_x_SMA50_Sell @ $64.88
Insider Activity
Recent Transactions (Last 10):
- Buys: 1
- Sells: 9
Notable Transactions:
- 2026-03-11: HENDERSON MICHAEL THOMAS - Sell (Sale, 8,363 shares @ $74.29)
- 2026-03-11: HENDERSON MICHAEL THOMAS - Sell (Sale, 8,219 shares @ $74.83)
- 2026-03-11: HENDERSON MICHAEL THOMAS - Sell (Sale, 3,418 shares @ $75.86)
News Sentiment Analysis
AI Analysis (based on 30 recent articles):
News sentiment for Apogee Therapeutics (APGE) is strongly positive, fueled by encouraging Phase 2 eczema drug data showing durable responses with 75-85% EASI-75 maintenance, positive interim asthma results, and accelerated pipeline milestones. The stock has rallied significantly, hitting new 52-week highs, with major institutional investors increasing stakes and analysts maintaining a 'Moderate Buy' rating. Minor insider sales are overshadowed by overall optimism and conference participations.
Key Themes:
- Strong Clinical Data Readouts
- Stock Rallies and Highs
- Institutional Buying and Analyst Support
Sentiment: Positive (95% confidence)
Recent News
5 most recent articles covering APGE:
- Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout (benzinga.com, 2026-03-23) — Read more
- How Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema Drug (investors.com, 2026-03-23) — Read more
- Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis (globenewswire.com, 2026-03-23) — Read more
- Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 (globenewswire.com, 2026-03-22) — Read more
- Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results (globenewswire.com, 2026-03-02) — Read more
Full news analysis based on 30 recent articles
Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-03-23 11:18:20 AM PDT
Disclaimer: This is not investment advice. Always do your own research before making investment decisions.